Based on fourteen case reports from various centres from 1992-2015 and three original studies in [2006][2007][2008][2009][2010][2011] 122 fetuses were subjected to analysis. In these reports, transplacental digoxin treatment was administered to different cardiac anomalies such as SVT , Ebstein's anomaly, critical AS , absent pulmonary valve syndrome, complete heart block, in foetuses with aneurysm/diverticulum of LV, in tricuspid atresia or dysplasia, rhabdomyoma, pulmonary atresia, HLHS with fibroelastosis, in TTTS and in extracardiac anomalies such as atriovenous malformation or sacrococcygeal teratoma. There was no statistical difference to suggest (Chi-square test) that digoxin was more efficient to control fetal arrhythmias than fetal congestive heart failure in nonarrhythmic patients.
INTRODUCTION
Digoxin, a purified cardiac glycoside derived from digitoxin extracted from the woolly foxglove (Digitalis kabata) purple foxglove (Digitalis purpurea), has strong inotropic and chronotropic effects on the heart. The positive inotropic activity increases the stroke and minute volume, while the negative chronotropic action slows the cardiac rhythm, which results from direct action of digoxin on the sinus node and stimulation of the centres of the vagus nerve. The primary indication for digoxin was to improve disorders of circulatory hemodynamics. 1 Digitalis glycosides are among the oldest drugs used in cardiology .Today, digoxin is occasionally used in the treatment of atrial fibrillation, atrial flutter and congestive heart failure that cannot be controlled by other medication. Currently, the general use of digoxin has been curtailed because of difficulties in efficient dosing, as well as the availability of newer and more effective drugs in paediatrics and adult cardiology.
Digoxin side effects are mainly cardiac arrhythmias, observed in about 20% of patients (A-V blocks type I, II and III AV, ventricular or supraventricular extrasystoles 2 .
Other symptoms of side effects are gastrointestinal symptoms (nosea, vomiting) and CNS disturbances (blurred vision). Because there is usually a small difference between the treatment dose and toxic dose, it is very easy to overdose the patient or to give subtherapeutic doses. Thus, close monitoring of plasma levels of digoxin and of the electrocardiogram are necessary.
In obstetrics, the transplacental treatment in healthy pregnant women with digoxin has been used for the management of prenatal cardiology for many years. 3,4,5,6,7,8,910,11,12,13,14,15,16, . Probably because of an increased blood volume in the third trimester of pregnancy and possibly other mechanisms, no side effects from digoxin affected majority of pregnant women, whereas an improvement of foetal hemodynamics was usually observed.
The literature about the use of digoxin during pregnancy is somewhat limited and there is no exhaustive analysis that directly answers questions about foetal hemodynamic improvement resulting from transplacental treatment with digoxin or spontaneous regression of earlier observed disorders.
MATERIALS AND METHODS
Fourteen case reports from various centres in the USA, Japan, Poland and Croatia during 1992-2015 (Table 1) and three original studies in 2006-2011 (Tables 2, 3 and  4) were subjected to our analysis. 7, 8, 13 In these reports, transplacental digoxin treatment was administered to different cardiac anomalies accompanied by generalised foetal oedemas, cardiac arrhythmia, cardiac insufficiency (Table 1) . For statistical analysis Chi-square test was used to analyse was digoxin more efficient to control fetal arrhythmias or fetal congestive heart failure? Uses", by the physician William Withering in 1785 is generally credited as marking the breakthrough of its use 2, 17 . Since the original report, cleaner preparations were developed and the purified compound was achieved in 1930. The foxglove has been saving lives of cardiac patients for more than 200 years. Today, despite significant side effects, digoxin still occupies a significant position in pharmacotherapy of heart diseases, however its application in cardiology has been reduced significantly 18 . At present, it is used mainly in monitoring the fast rhythm in persistent atrial fibrillation and in some cases of circulatory insufficiency.
DISCUSSION
The pioneers of the transplacental treatment of foetuses with digoxin were Kerenyi and Kleinman. In 1980 Kerenyi described treatment with digoxin in foetuses with SVT 19 , and in 1982 Kleinman published a case of a foetus with oedema caused by SVT and successful treatment with digoxin 20 . At present, it is assumed that the type of supraventricular contraction plays the most important role in the choice of anti-arrhythmia medication. Jaeggi and co-workers in 1998 and Fouron in 2000 commenced the new era in prenatal SVT treatment based on the selection of the medicine depending on the type of arrhythmias 21, 22 . In this review we analyzed the reports focusing on singleton pregnancies, but DeLia and Arabin published about digoxin in twin transfusion syndrome as an addition to laser resulting in foetal improvement 23, 24 .
Various ways of Digoxin application are possible in case of foetuses heart problem. The transplacental transfer is a main issue 25 . The concentration of digoxin in foetuses without oedema achieves about 40 -90% of maternal digoxin level 26 . However, in case of placental oedema its level is only 10% 2, 26 . In cases without symptoms of foetal circulatory insufficiency, oral administration is recommended for the pregnant woman 27, 28 . In cases of foetal circulatory insufficiency with oedema, the treatment with digoxin is started intravenously with subsequent oral administration 28 . In the most difficult cases, it is possible to apply digoxin directly to the foetus: via the umbilical vein, intramuscularly, intraperitoneally, to the amniotic fluid or to the heart 29, 30, 31, 32, 37 . It is assumed that the digoxin level in maternal serum should be about 2-2.5 ng/dL which is usually difficult to achieve and in 2-3 weeks of maternal digoxin treatment even lower level seems to be effective. Also maternal clinical condition and maternal ECG (prolongation of PR, QT , repolarisation, arrhythmias). are important.
The laboratory methods of serum digoxin assessment might be another problem as well as digoxin level in umbilical neonatal cord. In majority of the publications this was never mentioned.
Thus far, the international standards for prenatal treatment of foetal tachyarrhythmia have not been strictly unified. In Poland, the treatment of this group of arrhythmias is indicated in the Recommendations of Polish Gynaecology Association since 2006 33 , which are in agreement with the experiences of Polish Foetal Cardiologists 34, 35 .
Apart from foetal arrhythmias, digoxin may be used for foetuses with congestive heart failure, which might be due to different pathogenetic mechanisms:
• Ventricular diastolic overload (in the course of valvular incompetence, ventricular shunt) (63%) (37%)
• Ventricular systolic overload (in the course of arterial pulmonary and systemic hypertension, aortic or pulmonary stenosis)
• Myocardial dysfunction due to myocarditis or cardiomyopathy
In the publications about prenatal digoxin treatment, majority of information concern SVT 7, 12, 13,,14,15,16,19, 20, 21, 22, 26, 28, 29, 30, 31, 32, 34, 35, 38,39,40,41 . Digoxin treatment in cases other than SVT was applied in such abnormalities as: in foetuses with Ebstein's anomaly, critical AS , absent pulmonary valve syndrome, complete heart block, in foetuses with aneurysm/diverticulum of left ventricle, in tricuspid atresia or dysplasia, rhabdomyoma, pulmonary atresia, HLHS with fibroelastosis, in twin twin transfusion syndrome and in extracardiac anomalies such as atriovenous malformation or sacrococcygeal teratoma 4, 5, 6, 8, 9, 10, 11, 23, 24, 37, 42 .
Digoxin was applied several weeks, rather than days: from 6 up to 10 weeks. Regression of oedema and / or normalisation of foetal heart rhythm were observed. The published literature 9, 21, 22, 27, 35, 36, 37 suggests that despite the reduction of digoxin use in adult cardiology, its use in prenatal cardiology is still important, despite problems of monitoring maternal and fetal heart response.
Digoxin serum level includs both free and serum proteinbound drug. Approximately 20% of digoxin is typically bound to serum proteins, mainly albumin. Free digoxin concentrations reflect approximately 80% of the active compound. Using the radioimmunoassay technique for measuring serum digoxin, it was found that patients who were given 0.25 mg. digoxin orally per day had a mean serum level of 0.83 +/-0.06 ng. per ml. In patients given 0.5 mg. daily the mean level was 1.30 +/-0.14 ng. The therapeutic plasma levels are 0.7 to 2.0 ng/ml for digoxin. Individuals who exhibited electrocardiographic evidence of digoxin toxicity had a mean serum level of 2.81 +/-0.21 ng. The majority of patients with high serum levels had evidence of impaired renal function, but also digitalis intolerance maybe an issue or interaction of glycosides with other drugs. Repeated measurements on the same patient on maintenance therapy showed little variation. To obtain dependable serum levels blood in adults should be drawn at least five hours after oral, and three hours after intravenous administration 43, 44 .
The situation during the pregnancy is even more complicated due to low molecular compoundsendogenous digitalis-like substances EDLS which cause increase naturesis. These EDLS are like cardiac glycosides and bind to cardiac glycoside-specific antibodies 45 .
The serum of women in the third trimester of pregnancy demonstrates increased levels of this digoxin-like immunoreactive substance(s) 46 . Digoxin-like immunoreactive substance (s), are also present in the placenta and are released into the fetal circulation and may play a role in placental control of fetal vascular tone 47 .
Digoxin-like immunoreactive substance(s) was isolated from sera and autopsy-derived tissue obtained from premature and full-term neonates. The highest tissue level of DLIS was in the small bowel followed by the adrenal, gallbladder and liver. Of the fluids examined, meconium had the highest level of DLIS. Preparative high performance liquid chromatography fractionation of cord blood generated at least six different fractions of these substances 48 .
One of the concern to use digoxin for therapeutic purpose is the possibility of its toxicity. However since 70 ties there is known antidotum such as digoxin-specific antibody fragments (Fab) for treatment of digitalis intoxication 49, 50, 51 . However even despite the lack of Fab the proper cardiac care of intoxicated patient may by crucial and life saving 52 With our present knowledge about digoxin and the development of prenatal echocardiography, and with reference to its pioneer, the use of digoxin is still accepted in different cases of prenatal cardiac insufficiency in tertiary centers for fetal cardiology.
Prenatal cardiology is a rather new and growing field. The experiences of administering digoxin in pregnancy might cause a comeback of the digoxin golden era. We were not able to prove its advantages in fetal arrhythmias comparing with other problemes and heart insufficiency ( Table 4 ). Our observations may not be as important as those of William Withering, but may nevertheless contribute to an interest in digoxin by foetal cardiologists who care for pregnant women. Alternatively, newer pharmaceutical preparations, now under development, might replace digoxin as the preferred medication for foetuses with cardiac disease.
CONCLUSIONS
Foetal cardiac insufficiency may appear due to different reasons (in normal heart anatomy or in heart defects, in normal sinus rhythm or due to foetal arrhythmias: tachycardias or severe bradycardia) and may be a cause of intrauterine demise. So far, we do not have strong evidence that digoxin treatment may prevent foetal death or prematurity. More research is needed to ascertain if the prolonging of pregnancy resulted from digoxin treatment or if improvement in foetal circulatory insufficiency was influenced by spontaneous regression of foetal cardiac symptoms.
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